Daiichi Sankyo’s US CEO and head of global oncology Ken Keller explains what his expectations are for JP Morgan prior to the conference.
Ken Keller
Advertisement
Articles by Ken Keller
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Pharmaceutical Executive Daily: Continued Coverage of the 2026 J.P. Morgan Healthcare Conference
2
JP Morgan 2026: Novavax Shifting Towards Partnership-Driven Strategy
3
JP Morgan 2026: AbbVie Advances its Pipeline
4
Making the Transition From Frontline Biopharmaceutical Sales to Wealth Management Advisory
5